Immune therapy meets precision medicine

Affiliations

¹ Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria; Department of Urology and Division of Medical Oncology, Weill Medical College of Cornell University, New York, NY, USA; Department of Urology, University of Texas Southwestern, Dallas, TX, USA. Electronic address: shahrokh.shariat@meduniwien.ac.at.
² Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.

Comment

Shahrokh F Shariat et al. Lancet Oncol. 2017 Mar.

. 2017 Mar;18(3):271-273.

doi: 10.1016/S1470-2045(17)30098-0. Epub 2017 Mar 2.

¹ Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria; Department of Urology and Division of Medical Oncology, Weill Medical College of Cornell University, New York, NY, USA; Department of Urology, University of Texas Southwestern, Dallas, TX, USA. Electronic address: shahrokh.shariat@meduniwien.ac.at.
² Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.

No abstract available

Comment on

Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial.
Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J, Plimack ER, Vaena D, Grimm MO, Bracarda S, Arranz JÁ, Pal S, Ohyama C, Saci A, Qu X, Lambert A, Krishnan S, Azrilevich A, Galsky MD. Sharma P, et al. Lancet Oncol. 2017 Mar;18(3):312-322. doi: 10.1016/S1470-2045(17)30065-7. Epub 2017 Jan 26. Lancet Oncol. 2017. PMID: 28131785 Clinical Trial.